New Diabetes Pill Delivers 90% Success Rate in Major Trial

For people with type 2 diabetes, a promising new pill just delivered results that researchers are calling remarkable.

In a major clinical trial involving 406 adults across nine countries, an experimental medication called elecoglipron helped nearly 90% of participants achieve healthy blood sugar control. That's compared to just 25% in the placebo group.

The study, called SOLSTICE and presented at the American Diabetes Association's Scientific Sessions, tested various doses of the oral GLP-1 medication over 26 weeks. Results were simultaneously published in The Lancet, one of medicine's most prestigious journals.

Dr. Vanita Aroda from Mass General Brigham led the research. She directs diabetes clinical research in the hospital system's Division of Endocrinology, Diabetes & Hypertension.

"Our study's findings underscore the expanding potential of oral GLP-1 receptor agonists for people with type 2 diabetes," Aroda said. The medication addresses key limitations of current treatments while delivering powerful results.

Beyond blood sugar control, participants experienced meaningful weight loss. Up to 72% of people taking elecoglipron lost at least 5% of their body weight, compared to just 20% receiving placebo.

Most current GLP-1 medications require injections, which many patients find challenging to maintain. One existing pill option, semaglutide, comes with strict requirements: it must be taken first thing in the morning on an empty stomach, with no food or water for 30 minutes afterward.

Elecoglipron was specifically developed to overcome these barriers. The pill offers a simpler daily routine while delivering results comparable to injectable options.

The Ripple Effect

The breakthrough extends far beyond convenience. An estimated 37 million Americans live with diabetes, with type 2 accounting for about 90% of cases. Worldwide, over 500 million people manage the condition.

Many patients struggle with current treatment regimens. Injectable medications create barriers related to needle anxiety, storage requirements, and the challenge of consistent self-administration. Complex dosing schedules for existing oral options lead to missed doses and reduced effectiveness.

A simple, effective pill could dramatically improve treatment adherence. When patients can easily stick to their medication routine, health outcomes improve across the board: fewer complications, reduced hospitalizations, and better quality of life.

The medication's safety profile aligned with other GLP-1 therapies at this stage of development. Researchers continue evaluating the drug to ensure it meets all safety standards before potential approval.

Aroda also serves as principal investigator for another promising diabetes study, REIMAGINE 1, which showed 87% of participants reaching target blood sugar levels with a different combination therapy.

"At the center of every one of our clinical trials is the goal of improving outcomes for patients," Aroda explained. These carefully designed studies ensure that scientific advances translate into safer, more effective care for people living with diabetes.

The research represents real progress toward making powerful diabetes treatment accessible and manageable for millions who need it most.